NILVANSTOMIG

UNII:	2NQG7P8ET6
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	NILVANSTOMIG
GSRS Full Record:	2NQG7P8ET6 i

3061475-22-4
H-gamma4 heavy chain anti-PDCD1 fused to a scFvhk anti-TIGIT (H) (1-713) [H-gamma4 heavy chain anti-PDCD1 humanized (1-444) [VH (Homo sapiens IGHV1-46*01 (85.6%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1-117)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10 (CH1 (118-215), hinge 1-12 S10>P (225) (216-227), CH2 L92 (306) (228-337), CH3 (338-442), CHS (443-444)) (118-444)] -10-mer bis(tetraglycyl-seryl) linker (445-454) -scFvhk anti-TIGIT humanized (455-713) [VH (Homo sapiens IGHV1-46*01 (98.0%) -IGHD -IGHJ4*01 (100%), CDR-IMGT [8.8.15] (480-487.505-512.551-565)) (455-576) -30-mer hexakis(tetraglycyl-seryl) linker (577-606) -V-KAPPA (Homo sapiens IGKV1-39*01 (93.7%) -IGKJ1*01 (100%), CDR-IMGT[6.3.9] (633-638.656-658.695-703)) (607-713)]]; (131-214')-disulfide with L-kappa light chain anti-PDCD1 humanized (L') (1'-214') [V-KAPPA (Homo sapiens IGKV1-9*01 (84.2%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (223-223'':226-226'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa
Immunoglobulin G4, bispecific, anti-(human/Macaca fascicularis programmed cell death protein 1) (human-Mus musculus monoclonal 2P17 γ4-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human/Macaca fascicularis receptor TIGIT) (human-Mus musculus monoclonal B21-35 single-chain variable fragment VH-(GGGGS)6-VL), disulfide with human-Mus musculus monoclonal 2P17 κ-chain, dimer
Nilvanstomig
immunoglobulin (H-gamma4-scFvhk_L-kappa) dimer, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)] and anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], humanized monoclonal antibody, bispecific, tetravalent (nilvanstomig)
nilvanstomig [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

NILVANSTOMIG

Synonyms and Mappings

Resources